$906 Million is the total value of Atlas Venture Life Science Advisors, LLC's 17 reported holdings in Q3 2022. The portfolio turnover from Q2 2022 to Q3 2022 was 6.2% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| New | Third Harmonic Bio, Inc. | $206,922,000 | – | 10,907,859 | +100.0% | 22.84% | – | |
| DAWN | Sell | Day One Biopharmaceuticals, Inc. | $163,628,000 | +1.9% | 8,169,171 | -8.9% | 18.06% | -32.7% |
| KYMR | Kymera Therapeutics, Inc. | $149,684,000 | +10.6% | 6,875,698 | 0.0% | 16.52% | -27.0% | |
| DYN | Dyne Therapeutics, Inc. | $113,473,000 | +84.9% | 8,934,902 | 0.0% | 12.52% | +22.0% | |
| REPL | Sell | Replimune Group, Inc. | $53,680,000 | -4.3% | 3,108,300 | -3.2% | 5.92% | -36.8% |
| Vigil Neuroscience, Inc. | $53,116,000 | +252.7% | 5,836,874 | 0.0% | 5.86% | +132.8% | ||
| GBIO | Generation Bio, Co. | $43,961,000 | -19.1% | 8,278,876 | 0.0% | 4.85% | -46.6% | |
| AVTE | Sell | Aerovate Therapeutics, Inc. | $38,597,000 | -6.4% | 2,327,909 | -11.8% | 4.26% | -38.2% |
| AKRO | Sell | Akero Therapeutics, Inc. | $33,854,000 | +60.5% | 994,251 | -55.5% | 3.74% | +5.9% |
| IKNA | Ikena Oncology, Inc. | $17,815,000 | -19.9% | 5,018,178 | 0.0% | 1.97% | -47.1% | |
| GMTX | Gemini Therapeutics, Inc. | $8,617,000 | -3.0% | 5,254,365 | 0.0% | 0.95% | -36.0% | |
| Xilio Therapeutics, Inc. | $8,030,000 | -0.3% | 2,759,344 | 0.0% | 0.89% | -34.2% | ||
| MGTA | Magenta Therapeutics, Inc. | $4,902,000 | +17.5% | 3,476,536 | 0.0% | 0.54% | -22.4% | |
| FSTX | F-star Therapeutics, Inc. | $3,070,000 | -18.2% | 599,524 | 0.0% | 0.34% | -45.9% | |
| AVRO | AvroBio, Inc. | $2,905,000 | -30.2% | 4,520,863 | 0.0% | 0.32% | -53.8% | |
| SPRO | Spero Therapeutics, Inc. | $2,062,000 | +169.9% | 1,031,160 | 0.0% | 0.23% | +78.1% | |
| VRDN | Viridian Therapeutics, Inc. | $1,847,000 | +77.3% | 90,072 | 0.0% | 0.20% | +17.2% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-11-09
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Kymera Therapeutics, Inc. | 8 | Q3 2023 | 40.1% |
| Day One Biopharmaceuticals, Inc. | 8 | Q3 2023 | 26.8% |
| Dyne Therapeutics, Inc. | 8 | Q3 2023 | 15.4% |
| Replimune Group, Inc. | 8 | Q3 2023 | 9.4% |
| Generation Bio, Co. | 8 | Q3 2023 | 9.1% |
| Aerovate Therapeutics, Inc. | 8 | Q3 2023 | 7.2% |
| Akero Therapeutics, Inc. | 8 | Q3 2023 | 4.3% |
| Ikena Oncology, Inc. | 8 | Q3 2023 | 5.8% |
| Xilio Therapeutics, Inc. | 8 | Q3 2023 | 4.1% |
| AVROBIO INC | 8 | Q3 2023 | 1.6% |
View Atlas Venture Life Science Advisors, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-09 |
| 13F-HR | 2023-11-13 |
| 13F-HR | 2023-08-11 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-09 |
| 13F-HR | 2022-08-03 |
| 13F-HR | 2022-05-16 |
| 13F-HR | 2022-05-16 |
View Atlas Venture Life Science Advisors, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.